OTCBB:RZLT
Rezolute, Inc. Stock News
$4.21
-0.1000 (-2.32%)
At Close: Jul 02, 2024
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
08:00am, Monday, 24'th Jun 2024
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative t
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
11:30pm, Thursday, 13'th Jun 2024
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative t
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:01pm, Thursday, 13'th Jun 2024
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative t
Rezolute to Participate in the Jefferies Global Healthcare Conference
08:00am, Thursday, 30'th May 2024
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, t
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
04:05pm, Tuesday, 21'st May 2024
Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease in
$DED: What Do We Know So Far?
11:28am, Monday, 20'th May 2024
The last few months have seen the Polkadot network come back to life, and ironically, a project called “Dot is Ded” is behind that. Backed by the $DED token, this grassroots memecoin has gone out
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
04:05pm, Wednesday, 15'th May 2024
Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
08:00am, Tuesday, 23'rd Apr 2024
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel,
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
03:43pm, Monday, 15'th Apr 2024
Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
07:30am, Wednesday, 06'th Mar 2024
Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) Potential to more than double the addr
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
04:05pm, Tuesday, 13'th Feb 2024
Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
08:00am, Wednesday, 24'th Jan 2024
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious
REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
08:00am, Thursday, 14'th Dec 2023
Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025 Company anticipates completing enrollment by the end of 2024 and reporting topline results i
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
08:00am, Wednesday, 13'th Dec 2023
REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious
